Trial Profile
Phase II Cardiac Safety trial of liposomal pegylated doxorubicin in patients with breast cancer with non evidence of disease and previous exposition to Anthracyclines.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 31 May 2011 New trial record